USPTO Examiner LAZARO DOMINIC - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18915144READY-TO-USE SODIUM PHOSPHATES INJECTIONOctober 2024February 2025Allow410YesNo
18730659SINGLE-DOSE COSMETIC PRODUCT AND PROCESS OF MANUFACTURING THEREOFJuly 2024February 2025Allow700YesNo
18667826READY-TO-USE SODIUM PHOSPHATES INJECTIONMay 2024July 2024Allow200YesNo
18653070METHODS FOR SHRINKING PITUITARY TUMORSMay 2024March 2025Allow1010YesNo
18645654DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSApril 2024April 2025Allow1110NoNo
18639748COMPOSITION COMPRISING OIL PALM PHENOLICS FOR USE IN THE TREATMENT AND PREVENTION OF COLON DISEASES AND FOR PROMOTING AND MAINTAINING GUT AND GENERAL HEALTHApril 2024March 2025Allow1110YesNo
18628073HIGHLY CRYSTALLINE ALPHA-1,3-GLUCANApril 2024February 2025Allow1010NoNo
18606860THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONSMarch 2024March 2025Allow1220NoNo
18589336Compositions, Kits, Methods and Uses for Cleaning, Disinfecting, Sterilizing and/or TreatingFebruary 2024March 2025Allow1320NoNo
18441673METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS VIA ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINFebruary 2024February 2025Allow1210YesNo
18436480DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSFebruary 2024December 2024Allow1010NoNo
18436682DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOFFebruary 2024November 2024Allow910NoNo
18431234DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSFebruary 2024December 2024Allow1010NoNo
18405634HYDROGELS AS RHEOLOGY MODIFIERS AND METHODS OF MAKING THE SAMEJanuary 2024November 2024Allow1110NoNo
184034062-OXO-2-({2-[(PHENYLCARBAMOYL)OXY]ETHYL}AMINO)ETHYL PHENYLCARBAMATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024May 2024Allow500YesNo
18538903IMPLANT WITH FILLABLE RESERVOIRDecember 2023April 2025Allow1610YesNo
18379505BALLOON CATHETERS FOR BODY LUMENSOctober 2023August 2024Allow1110NoNo
18379190DERMAL FILLERS AND APPLICATIONS THEREOFOctober 2023May 2024Allow700YesNo
18376044METHODS AND COMPOSITIONS FOR WOUND HEALINGOctober 2023August 2024Allow1010NoNo
18372657NANO-SIZED MIXED LIGAND [4-BROMO-2-(QUINOLIN-2-YLIMINOMETHYL)-PHENOL IMINE- PHENANTHROLINE] RU(III) COMPLEX FOR MEDICINAL APPLICATIONSSeptember 2023December 2023Allow200YesNo
18362431NOVEL ORAL LIQUID COMPOSITIONS OF ENZALUTAMIDE AND METHOD OF MANUFACTURING THEREOFJuly 2023August 2024Allow1211NoNo
18220371COMPOSITIONS AND METHODS FOR TREATING INTERVERTEBRAL DISCSJuly 2023June 2024Allow1220YesNo
18219837DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURESJuly 2023March 2025Allow2020NoNo
18345683Multi-Functional Hemocompatible Porous Bead Sorbent For Removing Protein Based Toxins And Potassium From Biological FluidsJune 2023September 2024Allow1510NoNo
18214131DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURESJune 2023June 2024Allow1110NoNo
18329841Adhesive Containing MicroparticlesJune 2023April 2024Allow1010YesNo
18205283PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLSULFONAMIDES, AND THEIR THERAPEUTIC APPLICATIONSJune 2023September 2024Abandon1510NoNo
18201709AMTIMICROBIAL SILICONESMay 2023August 2024Abandon1510NoNo
18315448THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITORMay 2023March 2024Allow1110NoNo
18138583ZINC OXIDE PARTICLES, PHOTOSTABLE UV FILTERS, AND METHODS OF USE THEREOFApril 2023May 2024Allow1210NoNo
18123630GREEN SYNTHESIS OF SILVER NANOPARTICLES USING EUPHORBIA DENDROIDES AQUEOUS EXTRACTMarch 2023August 2023Allow501NoNo
18184845HIGHLY CRYSTALLINE ALPHA-1,3-GLUCANMarch 2023February 2024Allow1110NoNo
18117174Novel Retenoic Acid EstersMarch 2023December 2023Abandon910NoNo
18117152Novel RetinoatesMarch 2023December 2023Abandon1020NoNo
18112636TWO-STAGE MICROPARTICLE-BASED THERAPEUTIC DELIVERY SYSTEM AND METHODFebruary 2023November 2024Abandon2011NoNo
18170246THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTIONFebruary 2023January 2024Allow1110NoNo
18109328DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOFFebruary 2023November 2023Allow910YesNo
18163060COMPOSITIONS, SYSTEMS, AND METHODS FOR ORAL DELIVERYFebruary 2023June 2024Allow1611YesNo
18099147NON-WINTERIZED, STANDARDIZED MARINE SOURCE OIL PRODUCTS AND METHODS OF MAKING THEREOFJanuary 2023January 2024Allow1210NoNo
18098370DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSJanuary 2023December 2023Allow1120NoNo
18097698BALLOON CATHETERS FOR BODY LUMENSJanuary 2023July 2023Allow610NoNo
18097690DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURESJanuary 2023June 2023Allow510NoNo
18074577Skin Care CompositionDecember 2022March 2024Abandon1611NoNo
18071110CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOFNovember 2022April 2025Allow2921YesNo
17992715ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOFNovember 2022December 2023Allow1220NoNo
17992707THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONSNovember 2022November 2023Allow1220NoNo
17992703THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONSNovember 2022November 2023Allow1220NoNo
18056387LONG ACTING GASTRIC RESIDENCE SYSTEMNovember 2022October 2023Allow1110NoNo
17967259DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSOctober 2022November 2023Allow1310NoNo
17951321DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURESSeptember 2022October 2023Allow1210NoNo
17947058METHOD FOR CONTINUOUS FABRICATION OF MULTI-FUNCTIONAL NANOGELSSeptember 2022January 2024Allow1611YesNo
17944259DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSSeptember 2022November 2023Allow1410NoNo
17823120METHODS OF USING POLYMERSAugust 2022December 2024Allow2830YesNo
17799754COSMETIC COMPOSITIONS CONTAINING LOW MOLECULAR WEIGHT AMORPHOUS GRADE POLYLACTIC ACID RESINAugust 2022June 2025Allow3400YesNo
17760125COMPOSITION FOR RESTORATION OF TISSUE INCLUDING BIODEGRADABLE POLYMERIC COPOLYMERAugust 2022May 2025Allow3410NoNo
17816008HERBAL SHAMPOO COMPOSITION AND METHOD FOR PREPARING THE SAMEJuly 2022December 2022Allow510NoNo
17874412Non-Greasy Personal Care CompositionsJuly 2022January 2024Allow1710NoNo
17873818SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONSJuly 2022July 2023Allow1200NoNo
17867252AMTIMICROBIAL SILICONESJuly 2022March 2023Allow801YesNo
17811026ORAL ELIGLUSTAT TRANSMUCOSAL DELIVERY SYSTEMJuly 2022June 2023Allow1200YesNo
17849893Method of making an osteoconductive polymer article and an osteoconductive polymer article thus madeJune 2022March 2024Allow2110NoNo
17843208BALLOON CATHETERS FOR BODY LUMENSJune 2022July 2023Allow1310NoNo
17843150DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSJune 2022June 2024Allow2420NoNo
17833658Extracellular Matrix for Treating Pelvic Floor Disorders and Skeletal Muscle DegenerationJune 2022June 2023Allow1210NoNo
17825197HYDROGELS AS RHEOLOGY MODIFIERS AND METHODS OF MAKING THE SAMEMay 2022October 2023Allow1610NoNo
17776048DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATIONMay 2022April 2025Allow3510NoNo
17739037ANTERIOR SEGMENT DRUG DELIVERYMay 2022August 2024Allow2700NoNo
17774203BAKED CONFECTIONMay 2022May 2025Abandon3601NoNo
17763174METHODS AND FORMULATIONS FOR CROSSLINKING HAIR OR OTHER KERATIN FIBERS USING OXIDIZED SUGARS AS CROSSLINKING AGENTSMarch 2022March 2025Allow3611YesNo
17753841AGROCHEMICAL FORMULATION CONTAINING A SULFOPOLYMERMarch 2022June 2025Allow3910NoNo
17654786Compositions, Kits, Methods and Uses for Cleaning, Disinfecting, Sterilizing and/or TreatingMarch 2022October 2023Allow1920NoNo
17641093PLUNGER FOR A SYRINGE-TYPE PUMP FOR A MACHINE FOR ENCAPSULATION OF SOFT CAPSULES, AND SYRINGE-TYPE PUMP COMPRISING ONE OR MORE OF SAID PLUNGERSMarch 2022December 2024Allow3400NoNo
17679995IMPLANT WITH FILLABLE RESERVOIRFebruary 2022September 2023Allow1900YesNo
17673008ANTIMICROBIAL INSERTS FOR MEDICAL DEVICESFebruary 2022February 2025Allow3610NoNo
17562282REACTIVE DRY POWDERED HEMOSTATIC MATERIALS COMPRISING A PROTEIN AND A MULTIFUNCTIONALIZED MODIFIED POLYETHYLENE GLYCOL BASED CROSSLINKING AGENTDecember 2021July 2024Allow3111NoNo
17622392BIODEGRADABLE RESIN PARTICLES AND EXTERNAL PREPARATION INCLUDING THE SAMEDecember 2021July 2024Allow3100YesNo
17596413USE OF ABELMOSCHI COROLLA EXTRACT IN PREPARATION OF DRUG FOR TREATING FIBROSISDecember 2021May 2025Allow4110YesNo
17545886COSMETIC COMPOSITION COMPRISING A HYDROXYALKYL STARCH AS MAIN EMULSIFYING SYSTEMDecember 2021December 2023Abandon2510NoNo
17537789OIL-IN-WATER TYPE EMULSIFIED COSMETICNovember 2021April 2023Allow1700YesNo
17535102IMPLANTS HAVING A DRUG LOAD OF AN OXYSTEROL AND METHODS OF USENovember 2021July 2024Allow3221NoNo
17534415THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITORNovember 2021February 2023Allow1410NoNo
17531658BIOERODIBLE IMPLANT FOR LONG-TERM DRUG DELIVERY AND ASSOCIATED METHODS OF MANUFACTURE AND USENovember 2021July 2023Allow2010NoNo
17612945OXYGENATED CANNABIS SKIN THERAPY COMPOSITIONS AND METHODS FOR PRODUCING THE COMPOSITIONSNovember 2021March 2025Allow3901YesNo
17525074METHODS OF REPELLING BITING ARTHROPODS, REDUCING PATHOGEN SPREAD AND TREATING ARTHROPOD INFESTATIONNovember 2021June 2023Allow1910NoNo
17524467FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN THE GUTNovember 2021December 2023Abandon2501NoNo
17609601AN HERBO-MINERAL COMPOSITION FOR ALLEVIATING ADVERSE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTSNovember 2021October 2024Allow3500YesNo
17518157Implantable Materials and Uses ThereofNovember 2021March 2025Abandon4002NoNo
17499534Self-Emulsifying Bioactive ConcentratesOctober 2021December 2022Allow1410YesNo
17594130METHODS AND COMPOSITIONS FOR PROMOTING HEALTH IN A SUBJECTOctober 2021April 2025Abandon4201NoNo
17489915SYNERGISTIC COMPOSITION FOR OSTEOARTHRITISSeptember 2021September 2024Allow3610NoNo
17488720IRON-FORTIFIED FOOD COMPOSITIONSeptember 2021October 2022Allow1300NoNo
17599247Method of extracting caffeic acid and rosemarinic acid from rosemarySeptember 2021December 2024Allow3910YesNo
17486225PHARMACEUTICAL FORMULATIONSeptember 2021March 2025Allow4231NoNo
17449082Arthropod Pest Control Compositions, Kits and Uses ThereofSeptember 2021November 2023Abandon2510NoNo
17480687SYNERGISTIC ANTIOXIDANT COSMETIC COMPOSITION CONTAINING AT LEAST ONE HYDROXYTYROSOL AND AT LEAST ONE SULFORAPHANESeptember 2021October 2023Allow2410YesNo
17441573METHOD FOR EXTRACTING GYMNADENIA CONOPSEA AND RELATED GYMNADENIA CONOPSEA EXTRACTSeptember 2021April 2024Allow3100YesNo
17440355HIGH OIL CONTENT TOPICAL PERSONAL CARE PRODUCTSSeptember 2021November 2024Allow3810YesNo
17469385Biomedical FoamsSeptember 2021October 2023Allow2520YesNo
17410538MASKING SPRAYAugust 2021December 2023Abandon2810NoNo
17402473FLOWABLE COLLAGEN COLLOID AND METHOD OF FORMINGAugust 2021November 2024Abandon4021NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LAZARO, DOMINIC.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
25
Examiner Affirmed
19
(76.0%)
Examiner Reversed
6
(24.0%)
Reversal Percentile
36.2%
Lower than average

What This Means

With a 24.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
74
Allowed After Appeal Filing
16
(21.6%)
Not Allowed After Appeal Filing
58
(78.4%)
Filing Benefit Percentile
25.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LAZARO, DOMINIC - Prosecution Strategy Guide

Executive Summary

Examiner LAZARO, DOMINIC works in Art Unit 1611 and has examined 659 patent applications in our dataset. With an allowance rate of 61.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner LAZARO, DOMINIC's allowance rate of 61.5% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LAZARO, DOMINIC receive 2.27 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LAZARO, DOMINIC is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +37.0% benefit to allowance rate for applications examined by LAZARO, DOMINIC. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.6% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 34.8% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 54.5% of appeals filed. This is in the 20% percentile among all examiners. Of these withdrawals, 36.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.7% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.